File No.35024/18/2020-Scheme Government of India Ministry of Chemicals & Fertilizers Department of Pharmaceuticals

Shastri Bhawan, New Delhi Dated the 29th December, 2020

То

Pharmexcil, FICCI, CII, ASSOCHAM, PHD Chamber, IPA, IDMA, BDMA, FOPE, OPPI, AIMED, MTal, CIPI.

Subject:- 6th India Pharma and Medical Device Awards

Sir/Madam,

I am directed to say that Government of India, Ministry of Chemicals & Fertilizers, Department of Pharmaceuticals has decided to confer 6th India Pharma/Medical Device Awards during India Pharma 2021 & India Medical Device 2021. The categories/indicators for these Awards are attached as Annexure.

2. You are requested to disseminate the same amongst members of your organizations. Separate nominations for each category (along with supporting documents) may be sent to the undersigned. The last date for receipt of nominations is 15th January, 2021. No nomination will be accepted after the last date.

3. To get better response and giving wider publicity to awards you are requested to kindly upload the information about 6th India Pharma and Medical Device Awards on all social media platforms and website of your organization.

Encl:- As above

S. Rojalakshmi 29/12/2000 (S. RAJALAKSHMI) Deputy Secretary to the Govt. of India

Phone: 011-23311031

Copy to:-Senior Technical Director, NIC- for uploading the same on the website of Department of Pharmaceuticals.

Copy also to:- Chairman (NPPA), CMD (KAPL), CMD (IDPL), MD(HAL), MD (RDPL), CEO(BPPI)

Copy (along with enclosures) also to:- PS to Hon'ble Minister (C&F), PS to Hon'ble MoS (C&F), PSO to Secretary (Pharma), Consultant to JS(Policy), Consultant to JS(NIPER/PSU), PA to (EA), PA to Director (Krishna Kumar Pilli), Consultant to DS (Sumit Garg), DS (PK), DS (AVL), DS(BK), DS (S. Rajalakshmi), US(PSU), US(NIPER), US (Pricing), US (MD).

Criteria/Indicators for 6th India Pharma and India Medical Device Awards

1. India Pharma Leader Award

	Criteria		Indicators	Relevant information/ Documents to be furnished.
a.	Sales Turnover Growth in % (25% weightage) ,	•		Audited sales' figures for the last three financial years, duly certified by Company Secretary.
b.	Turnover of manufacturing in own plants as a Percentage of total turnover (25% weightage)		Highest of all entries received to have full marks and others proportionate	Audited figures on item- wise production in terms of quantity and value for different Pharma products manufactured in their own manufacturing facilities, in the previous year duly certified by Company Secretary
C.	Percentage of Sales of NLEMs vis-a-vis total Sales of Pharma products (20% weightage)		Highest of all entries received to have full marks and others proportionate	Audited figures of sales of NLEMs for last financial year, duly certified by Company Secretary
d.	Number of products launched in the last year (10% weightage)		Highest of all entries received to have full marks and others proportionate	List of products launched in the last year, duly certified by the Company Secretary.
e	Percentage of expenditure on R&D vis-a- vis total Annua Sales turnover averaged over 3 years (20% weightage)) r	Highest of all entries received to have full marks and others proportionate	Audited figures of expenditure on R&D incurred as a % of total sales, during last 3 financial years, duly certified by Company Secretary

A one page brief about the company along with name of important products being produced and its therapeutic significance

2. India Pharma Bulk Drug Company of the Year Award

	Criteria	Indicators Relevant information/ Documents to be furnished
a.	Increase in Sales in % terms over previous year (40% weightage)	 Highest of all entries received to have full marks and others proportionate The Company should indicate item-wise production and sales of Bulk Drugs in last 2 financial years duly certified by Company Secretary.
b.	Sales of Bulk Drugs, for use in manufacture of NLEM drugs as percentage of total Sales (30% weightage)	 Highest of all entries received to have full marks and others proportionate List of Bulk Drugs, together with item-wise production and sales figures, which are used in production of NLEMs, for the last financial year, duly certified by Company Secretary
C.	Increase in R&D expenditure on bulk drugs as Percentage over the previous financial year (30% weightage)	Highest of all entries Expenditure on R&D related to received to have full Bulk Drugs for the last 2 marks and others financial years, duly certified by proportionate Company Secretary.

A one page brief about the company along with name of important products being produced and its therapeutic significance

3. India Pharma Innovation of the Year Award

Criteria	Indicators	Relevant information/ Documents to be furnished
Number, of patents files and commercialized during the last 3 financial years 1) No. of product patents filed - 25% 2) No. of product patents granted- 25% 3) No. of product patents commercialized- 25% 4) Percentage of patents /innovations commercialized during the last 3 financial years pertaining to NLEM drugs. (25% weightage)	entries received to have full marks and others proportionate	during the last 3 financial

A one page brief about the company along with name of important products being produced and its therapeutic significance

4. India	Pharma	Corporate	Social	Responsibility	(CSR)	Programme	of t	the	Year
Award:	٠								

Criteria	Relevant information/ Documents to be furnished
• Details of CSR activities undertaken	 Details of activities undertaken under Corporate Social Responsibility Total expenditure incurred on these activities for the last 3 years, duly certified by Company Secretary. Geographical coverage of the CSR activities and approximate impact on the number of people.
The Jury to decided	

A one page brief about the company along with name of important products being produced and its therapeutic significance

Category 5- India Medical Devices Company of the Year Award

.

	Criteria	Indicators	Relevant information Documents to be furnished		
1	2	3	4		
a.	Sales Turnover increase in % over previous year (50% weightage)	 Percentage growth in Sales turnover over previous year. Highest of all entries received to have full marks and others proportionate 	 Give details of the Medical Devices and their sales turnover during the last 2years, duly certified by Company Secretary. Contents of different Medical Devices produced in terms of value of content achieved. 		
b.	R&D expenditure as a % of Sales (50% weightage)	 Percentage R&D expenditure on Sales turnover Highest of all entries received to have full 	 R&D expenditure in terms of percentage of sales incurred during the last year, duly certified by Company Secretary. 		

A one page brief about the company along with name of important products being produced

Note:

- Comparisons would be made based on audited results of the Financial Year 2019-20 and previous years
- Unaudited results would not be considered for evaluation
- No company would be conferred an Award in 2 categories in the same year. In case such a situation arises, the award appearing first in the list of Awards would be conferred and the second award would be given to the applicant with the next highest marks.
- The same category of award would not be conferred to the same company for 2 years in succession.
